**Reflection Agent Review – Cycle 2 Hypotheses**  
*Review mode: experimental design, falsifiability, controls, feasibility.*  
*All hypotheses are assessed against the mandatory Seurat/Public‑data analyses as summarized in the cycle evidence base.*

---

### Hypothesis ID: Axis1_AMD1_immune (from generation_metabolic)

**Review decision:** Promising but incomplete

**Directional assessment:**  
- **Strengths:** Direct metabolite (methionine) + enzyme (Amd1) anchor; MK‑enriched and PH‑up; immune‑mediated axis is plausible because polyamines are known immunomodulators.  
- **Weaknesses:** The polyamine‑immune link in the hypoxia‑PH lung remains speculative; no whole‑lung polyamine measurement; no MK‑to‑immune‑cell spatial evidence.  
- **Reasoning quality:** Good – connects methionine‑AMD1 to polyamine production and proposes a broad immune‑mediated route, explicitly labelling candidate examples (Th17) as provisional.  
- **Appropriate resolution:** Correctly stays at directional level without over‑resolving immune subsets.

**Evidence assessment:**  

| Source | Level | Details |
|--------|-------|---------|
| User‑provided scRNA‑seq | Direct | *Amd1* MK enriched, PH‑up (log2FC 1.77) |
| User‑provided metabolomics | Direct | Methionine up in PH‑MKs (log2FC 3.26) |
| Public data (GSE289322) | Not available | DE/GSEA results missing; cannot assess tissue‑level corroboration |
| Literature | Inferred | Polyamines influence T‑cell/macrophage function in other contexts; no direct PH‑MK studies |
| Biological inference | Speculative | MK‑derived polyamines reach perivascular immune cells at functional concentrations |

**Major concerns:**  
- Polyamines (spermidine/spermine) were not measured in MKs or whole lung – chain is inferred only from methionine and *Amd1* expression.  
- No demonstration that Amd1 knockout reduces polyamines in MKs under hypoxia.  
- The immunosuppressive/pro‑remodeling net effect of polyamines in the lung is unproven.

**Downstream‑axis assessment:**  
- **Broad axis:** Immune‑mediated (polyamines → T‑cell/Th17‑like skew, macrophage modulation).  
- **Candidate examples:** Spermidine‑suppressed Treg, enhanced IL‑17 (provisional).  
- **What remains unresolved:** Immune cell target(s), spatial range of MK‑derived polyamines, required concentration.  
- **MK‑origin gap:** Not addressed – MK proximity to immune niches not shown.  
- **Falsification criterion:** Adequate – *Amd1*‑KO should reduce perivascular immune activation and muscularization; if immune changes absent despite reduced polyamines, axis disproven.

**Required revisions:**  
- Explicitly acknowledge absence of polyamine measurement and propose direct polyamine quantification in MKs/lung tissue.  
- Add control: *Amd1*‑KO rescue with exogenous spermidine to confirm polyamine‑specific effect.

**Experimental critique:**  
- **Strong points:** Conditional *Amd1*‑KO (Pf4‑Cre) is well‑suited; flow‑based immune profiling coupled with muscularization is feasible.  
- **Weak points:** No direct readout of polyamine concentrations in perivascular niche; immune readouts are broad.  
- **Missing controls:** Littermate WT controls; Amd1‑flox without Cre; pharmacological polyamine blocking (DFMO) as complementary approach; polyamine replacement to test specificity.  
- **Falsification criteria:** Well defined: if MK‑specific Amd1 deletion fails to alter immune composition or muscularization, the immune axis is unsupported.

**Final recommendation:** **Revise** – include direct polyamine quantification, and add orthogonal falsification with polyamine synthesis inhibitors (e.g., DFMO) to confirm a polyamine‑dependent step.

---

### Hypothesis ID: Axis2_AMD1_vascular (from generation_metabolic)

**Review decision:** Promising but incomplete

**Directional assessment:**  
- **Strengths:** Polyamines are known smooth muscle cell mitogens; MK‑enriched AMD1 with methionine accumulation supports a paracrine mitogen role.  
- **Weaknesses:** No evidence of polyamine concentrations in the vessel wall; MK spatial proximity to PASMCs not established; receptor‑level mechanism undefined.  
- **Reasoning quality:** Acceptable – suggests direct mitogenic action on PASMCs, with eIF5A hypusination as a candidate example.  
- **Appropriate resolution:** Keeps direct vascular‑wall axis broad, does not over‑specify receptor.

**Evidence assessment:**  

| Source | Level | Details |
|--------|-------|---------|
| User scRNA‑seq + metabolomics | Direct | Amd1/methionine data |
| Public data | Missing | GSE289322 DE for proliferation signatures not available |
| Literature | Inferred | Polyamines can promote PASMC growth in systemic vessels; no PH‑MK evidence |
| Inference | Speculative | MK‑derived polyamines reach PASMCs at mitogenic levels |

**Major concerns:**  
- No MK‑to‑PASMC proximity data; lung MKs may be interstitial not directly adjacent to media.  
- Polyamine export mechanism unknown – are they secreted, released via EVs, or from cell lysis?  
- eIF5A hypusination is a candidate example; no data linking AMD1 to eIF5A hypusination in MKs.

**Downstream‑axis assessment:**  
- **Broad axis:** Direct vascular‑wall (polyamines → PASMC proliferation).  
- **Candidate examples:** Spermidine activating NMDA receptors or eIF5A hypusination (provisional).  
- **Unresolved:** MK proximity, polyamine transport, contribution relative to oxygen‑dependent PASMC responses.  
- **MK‑origin gap:** Not addressed.  
- **Falsification criterion:** Acceptable: if *Amd1*‑KO reduces polyamines but not PASMC proliferation, axis disproven.

**Required revisions:**  
- Include immunohistochemistry or spatial transcriptomics to show MK–PASMC co‑localization.  
- Measure spermidine/spermine in microdissected vessel wall.

**Experimental critique:**  
- **Strong points:** *Amd1*‑KO plus EdU/Ki67 readout in media is direct.  
- **Weak points:** Cannot distinguish direct mitogenic effect from secondary signals (e.g., hypoxia itself inducing proliferation); need polyamine‑specific blocker (e.g., DFMO) in addition to KO.  
- **Missing controls:** Pharmacological inhibition of polyamine synthesis in WT mice to mimic KO; rescue with spermidine infusion.  
- **Falsification criteria:** Sensible but will be confounded if MKs release other mitogens unaffected by Amd1 deletion.

**Final recommendation:** **Revise** – add spatial validation and a polyamine synthesis inhibitor arm to confirm pathway specificity.

---

### Hypothesis ID: Axis3_AMD1_EV (from generation_metabolic)

**Review decision:** Weak (conditional on mandatory Seurat results not yet verified)

**Directional assessment:**  
- **Strengths:** MKs are prolific EV producers; polyamines are small and could be packaged.  
- **Weaknesses:** EV biogenesis genes (*Rab27a*, *Tsg101*) expression in MKs is only self‑reported, not directly verified; polyamine loading into EVs not demonstrated; fibroblast activation endpoint is speculative.  
- **Reasoning quality:** Speculative chain – relies on EV machinery present and polyamine‑loading, which are untested.  
- **Appropriate resolution:** Acceptable if mandatory gene results are positive; currently unresolved.

**Evidence assessment:**  

| Source | Level | Details |
|--------|-------|---------|
| User scRNA‑seq (self‑reported) | Indirect | Rab27a enrichment reported, but not verified; Tsg101 modest increase |
| User metabolomics | Direct | Methionine, but no polyamine‑EV data |
| Public data | Missing | None |
| Literature | Inferred | EV metabolite loading is possible; no MK‑polyamine‑EV‑fibroblast studies |
| Inference | Speculative | Polyamines are loaded into MK‑EVs and delivered to fibroblasts |

**Major concerns:**  
- Entire axis depends on unconfirmed EV gene expression; if Rab27a/Tsg101 are not genuinely MK‑enriched or hypoxia‑responsive, the hypothesis collapses
